Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicity
作者： Mark Ratain , Lalitha Iyer , Michael Sawyer , Federico Innocenti , Soma Das
DOI:
关键词:
摘要: This invention concerns UGT2B7 and its ability to glucuronidate various drugs, including epirubicin. It methods compositions for determining the level of activity based on genetic composition, consequently, allows dosing UTG2B7-glucuronidated drugs be improved or optimized a patient's predicted activity. further treatment in which substrates are administered patients as part regimen.
google.ca 参考文章(8)
Michael Manns, Christian Strassburg, Method for the prediction of the risk potential for cancerous diseases and inflammatory intestinal diseases and corresponding tests ,(2002)
Mark J. Ratain, Elora Gupta, Camptothecin drug combinations and methods with reduced side effects ,(1995)
Lalitha Iyer, Anna Di Rienzo, Mark J. Ratain, Methods for detection of promoter polymorphism in a UGT gene promoter ,(2002)
Laura Penny, Margaret Galvin, Genotyping the human UDP-glucuronosyltransferase 1 (UGT1) gene ,(1999)
Janice Kurth, Marco Guida, Genotyping human UDP-glucuronsyltransferase 2B15 (UGT2B15) genes ,(2002)
Yoshinori Hasegawa, Yu-Uichi Ando, Kaoru Shimokata, Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme ,(2011)
Andrew Miller, Laura Penny, Margaret Galvin, Michael Riedy, Genotyping human UDP-Glucuronsyltransferase 2B15 (UGT2B15) genes ,(2002)
Dorothee Foernzler, Diane Uratsu Leong, Gonzalo Acuna, Method for detecting pre-disposition to hepatotoxicity ,(2001)